Additional file 3 of Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
posted on 2022-01-05, 04:43authored byOsman Öcal, Regina Schinner, Kerstin Schütte, Enrico N. de Toni, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Antonio Gasbarrini, Bruno Sangro, Maciej Pech, Peter Malfertheiner, Jens Ricke, Max Seidensticker
Additional file 3: Supplementary Fig. 3. Overall survival of patients with partial response according to depth of response (DpR) more or less than the median DpR. CI, confidence interval; HR, hazard ratio.
Funding
bayer healthcare sirtex Universitätsklinik München (6933)